Login to Your Account



Oxagen Spinout Atopix to Advance Allergy Pipeline

By Nuala Moran
Staff Writer

Tuesday, June 4, 2013
LONDON – A new company has been spun out of genomics pioneer Oxagen Ltd. to take forward the lead compound OC459 in fresh indications. The product has successfully completed Phase IIb development in asthma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription